newsfilter
← Latest News
GlobeNewswire·

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organicClosed BioLife acquisition, which fast-tracks Repligen’s leadership and offering in high-growth cell therapy market